You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Linear Growth Improves during Infliximab Therapy in Children with Chronically Active Severe Crohn's Disease

Walters, Thomas D. MBBS1; Gilman, Ashley R. BASc1; Griffiths, Anne M. MD1, *

Inflammatory Bowel Diseases:
doi: 10.1002/ibd.20069
Original Articles
Abstract

Background:: The efficacy of infliximab as maintenance therapy in patients with otherwise chronically active Crohn's disease (CD) is well established. Data concerning the linear growth response are sparse and can only be accrued in children.

Methods:: From September 2000 to February 2004, 32 children and adolescents (63% males; mean age 13.4 years, range 4.7–17.3) with chronically active CD despite immunomodulatory and prior corticosteroid therapy commenced infliximab therapy. Growth parameters standardized for age, gender, and pubertal development prior to and following infliximab therapy were compared.

Results:: In all, 28 of 32 patients tolerated and responded to the induction regimen and 27 responders continued to receive infliximab via regularly scheduled infusions (n = 22) or episodically (n = 5) for a median of 26 months. Mean standard deviation score (SDS) for height at time of initiation of infliximab therapy was −1.15 ± 1.2 and had declined despite the use of other therapies from −0.44 ± 1.1 at initial diagnosis. Increases in height velocity and stature during infliximab therapy were limited by pubertal stage: Tanner I–III: ΔSDS for height velocity +3.94, for height +0.50, P < 0.001; Tanner IV, V: ΔSDS for height velocity +0.22, for height 0.02, P = NS.

Conclusions:: Height velocity improves and height centile increases during infliximab therapy provided patients are treated prior to or in early puberty. These data support the use of infliximab in young patients with otherwise refractory disease, and suggest that ultimate height in this subset of children with severe CD may be less compromised than with previous therapies.

Author Information

1Division of Gastroenterology, Hepatology and Nutrition, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada

*Reprints: Professor of Paediatrics, Division of Gastroenterology/Nutrition, The Hospital for Sick Children, 555 University Ave., Toronto, Ontario M5G 1X8, Canada

E‐mail: anne.griffiths@sickkids.on.ca

Received for publication 11 May 2006; accepted 27 October 2006

Published online 19 December 2006 in Wiley InterScience (www.interscience.wiley.com).

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.